Abstract：
Nontuberculous mycobacteria (NTM) are a diverse group of mycobacterial species that are ubiquitous in the environment. They are opportunistic pathogens that can cause a range of diseases, especially in individuals with underlying structural lung disease or compromised immune systems.
This paper provides an in-depth analysis of NTM infections, including microbiology, environmental sources and transmission pathways, risk factors for disease, epidemiology, clinical manifestations and diagnostic approaches, guideline-based treatment recommendations, drugs under development, and management challenges.
Future approaches to the management of NTM pulmonary disease will require therapies that are well tolerated, can be taken for a shorter time period and perhaps less frequently, have few drug-drug interactions, and are active against the various strains of pathogens. As the numbers of infections increase, such therapies will be welcomed by clinicians and patients.
This paper provides an in-depth analysis of NTM infections, including microbiology, environmental sources and transmission pathways, risk factors for disease, epidemiology, clinical manifestations and diagnostic approaches, guideline-based treatment recommendations, drugs under development, and management challenges.
Future approaches to the management of NTM pulmonary disease will require therapies that are well tolerated, can be taken for a shorter time period and perhaps less frequently, have few drug-drug interactions, and are active against the various strains of pathogens. As the numbers of infections increase, such therapies will be welcomed by clinicians and patients.
摘要：
非结核分枝杆菌(NTM)是在环境中普遍存在的一组不同的分枝杆菌物种。它们是机会性病原体，可以在动物和人类中引起一系列疾病，尤其是在患有潜在结构性肺病或免疫系统受损的个体中。
■本文对NTM感染进行了深入分析，包括微生物学，环境来源和传播途径，疾病的危险因素，流行病学,临床表现和诊断方法，基于指南的治疗建议，正在开发的药物，和管理挑战。
■NTM肺病的未来治疗方法将需要耐受性良好的治疗方法。可以在更短的时间内服用，也许频率更低，几乎没有药物相互作用，并且对各种病原体菌株具有活性。随着感染数量的增加，这种疗法将受到临床医生和患者的欢迎。
■本文对NTM感染进行了深入分析，包括微生物学，环境来源和传播途径，疾病的危险因素，流行病学,临床表现和诊断方法，基于指南的治疗建议，正在开发的药物，和管理挑战。
■NTM肺病的未来治疗方法将需要耐受性良好的治疗方法。可以在更短的时间内服用，也许频率更低，几乎没有药物相互作用，并且对各种病原体菌株具有活性。随着感染数量的增加，这种疗法将受到临床医生和患者的欢迎。
